c-type natriuretic peptide
Peptideexperimental
Natriuretic peptide precursor C, also known as NPPC, is a protein that in humans is encoded by the NPPC gene. The precursor NPPC protein is cleaved to the 22 amino acid peptide C-type natriuretic peptide (CNP). — Wikipedia
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started Jan 1, 2017 (NCT01075776)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Atrial natriuretic factorSupplementation
NPPA supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaNatriuretic peptide precursor C ↗
Also known as
- c-type natriuretic peptide
- c-type natriuretic peptide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05929807 | Phase 2/Phase 3 (Phase 3) | Jun 21, 2023 | Ascendis Pharma, Inc. |
| NCT05598320 | Phase 2/Phase 3 (Phase 3) | Jan 31, 2023 | Ascendis Pharma, Inc. |
| NCT05246033 | Phase 2 | Jan 5, 2022 | Ascendis Pharma, Inc. |
| NCT04085523 | Phase 2 | Nov 30, 2019 | Ascendis Pharma, Inc. |
| NCT01075776 | N/A | Jan 1, 2017 | University of London |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ascendis Pharma, Inc. | For profit | 4 | 4 | 2 | 2019 |
| University of London | Academic/Hospital | 1 | 1 | 1 | 2017 |
2 organizations
Page 1 / 1